Key result
Mexiletine treats VA and LQTS by inhibiting Na+ currents despite ongoing mortality and proarrhythmia evaluations.
Why the study?
To examine the therapeutic benefits and potential risks of mexiletine and reinforce its role as a therapeutic option for ventricular arrhythmias, long QT syndrome, and other heart rhythm disorders.
This review provides a comprehensive overview of mexiletine's mechanisms, clinical applications, and safety profile in managing heart rhythm disorders.
Supports continued use in select ventricular arrhythmias and LQTS; leaves open mortality and proarrhythmic risks for prospective trials.
Mexiletine, a class Ib antiarrhythmic drug, exhibits its major antiarrhythmic effect via inhibition of the fast and late Na + currents in myocardial tissues that are dependent on the opening of Na + channels for their excitation. Through a comprehensive examination of mexiletine's therapeutic benefits and potential risks, we aim to provide valuable insights that reinforce its role as a vital therapeutic option for patients with ventricular arrhythmias, long QT syndrome, and other heart rhythm disorders. This review will highlight the current understandings of the antiarrhythmic effects and rationales for recent off‐label use and address the mortality and proarrhythmic effects of mexiletine utilizing published basic and clinical studies over the past five decades.
No takes yet. Share an insight, caveat, or question.
Olleik et al. (2023) conducted a review in Ventricular arrhythmias, long QT syndrome, and other heart rhythm disorders. Mexiletine was evaluated. Mexiletine serves as a vital therapeutic option for ventricular arrhythmias and long QT syndrome by inhibiting fast and late Na+ currents, with ongoing evaluation of its mortality and proarrhythmic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: